COMPANY

HCW Biologics

HQ: Miramar, FL source · hcwbiologics.com ↗ · Southeast

Keywords: oncology immunology autoimmune diseases cancer Alopecia Areata HCW9302, an IL-2 fusion protein

Location: Miramar, FL · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $4M (Form D filed Jun 8, 2026). SEC Form D 0001828673-26-000003 (Jun 8, 2026)
Evidence (1 event)
- Jun 8, 2026 · SEC Form D 0001828673-26-000003
  Name of Issuer: HCW Biologics Inc.; CIK: 1828673; Address: Miramar, FL; Submission type: D; Filing date: 2026-06-08; Industry Group: Biotechnology; Date of First Sale: 2026-05-21; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 24, 2026 Raise Private placement: $1.5M (total, as published), announced Sep 24, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 8, 2026 SEC Form D ↗
Jul 29, 2026 Raise Private placement: $1.6M (total, as published), announced Jul 29, 2026. Source: SEC filing. source ↗ · Form D filed Aug 6, 2026 SEC Form D ↗
Aug 16, 2025 Trial start Phase 1: HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata source ↗
Jun 4, 2025 Partnership Partnership / licensing: $7M (upfront, as published), announced Jun 4, 2025. Source: SEC filing. source ↗
Nov 18, 2024 Raise Follow-on offering — Registered direct: $6.9M (total, as published), announced Nov 18, 2024. Source: SEC filing. source ↗

Jul 16, 2027 (ESTIMATED) · Phase 1 · HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata · NCT07049328

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $10.0M. Last 2 years.

Sep 24, 2026 Private placement: $1.5M (total, as published), announced Sep 24, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 8, 2026 SEC Form D ↗
Jul 29, 2026 Private placement: $1.6M (total, as published), announced Jul 29, 2026. Source: SEC filing. source ↗ · Form D filed Aug 6, 2026 SEC Form D ↗
Nov 18, 2024 Follow-on offering — Registered direct: $6.9M (total, as published), announced Nov 18, 2024. Source: SEC filing. source ↗
Jun 4, 2025 Partnership / licensing: $7M (upfront, as published), announced Jun 4, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07049328	HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata	Phase 1	Recruiting	Aug 16, 2025	Jul 16, 2027 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

2026-10-08 Raise Private raise (SEC Form D): $1.5M sold; issuer “HCW Biologics Inc.”. Verified from the SEC filing. SEC filing ↗
2026-08-06 Raise Private raise (SEC Form D): $1.6M sold; issuer “HCW Biologics Inc.”. Verified from the SEC filing. SEC filing ↗
2026-06-08 Raise Private raise (SEC Form D): $4.0M sold; issuer “HCW Biologics Inc.”. Verified from the SEC filing. SEC filing ↗
2024-12-05 Raise Private raise (SEC Form D): $6.9M sold; issuer “HCW Biologics Inc.”. Verified from the SEC filing. SEC filing ↗